contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


enzymatica-ab-interim-report-q22023-an-exciting-and-important-time-ahead

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Enzymatica is a life science company that develops and sells medical devices against infectious diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray, which can prevent colds and shorten the duration of the illness. The product has been launched in several markets and the strategy is to expand to more markets through partners. The head office is located in Lund.

Enzymatica

Q2 H1Net sales reached SEK 8.8 (9.6) · Net sales reached SEK 21.8 (13.8)million. million.The operating result totaled SEK · The operating result totaled SEK-11.2 (-15.9) million. -25.5 (-34....

Q2 H1<ul><li>Net sales reached SEK 8.8 (9.6) · Net sales reached SEK 21.8 (13.8)</li></ul>million. million.<ul><li>The operating result totaled SEK · The operating result totaled SEK</li></ul>-11.2 (-15.9) million. -25.5 (-34.0) million.<ul><li>Earnings per share, basic and · Earnings per share, basic and</li></ul>diluted, were SEK -0.07 (-0.10). diluted, were SEK -0.16 (-0.22).<ul><li>Cash flow from operating · Cash flow from operating</li></ul>activities totaled SEK -9.5 (-21.5) activities totaled SEK -21.7 (-31.7) million. million.Significant events during the Significant events after the quarter quarter<ul><li>No significant events · No significant events were reported after</li></ul>were reported during the the end of the quarter. quarter. Other events during and after the quarter<ul><li>The University of Kent,</li></ul>UK, conducted a clinical study starting in November 2022 to investigate ColdZyme's effects in-vivo among elite athletes in endurance sports such as cycling and long-distance running. The results of the placebo-controlled, double -blind, and randomized study are expected in August 2023.<ul><li>The Medical University of</li></ul>Innsbruck, Austria, conducted an in vitro study during the second quarter to explore the effect of ColdZyme on human cells infected with influenza virus. The study results are expected in August 2023."The first half of 2023 showed 58% growth compared to the same period last year. The second quarter is always the weakest of the year for us, as it is the period when the number of colds is the lowest. Still, the second quarter was an intense period. Discussions on launches in some of the world's largest cold markets intensified and our research program continued. In August, we expect the results from two important scientific studies", said Claus Egstrand, CEO of Enzymatica.The full report is available on: www.enzymatica.com/investors/financial-reportsThis information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on July 18, 2023.For more information, please contact:Claus Egstrand, Chief Executive Officer, Enzymatica AB Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.comStefan Olsson, Communication Manager, Enzymatica AB Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.comEnzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank.